×
About 6,268 results

ALLMedicine™ Splenomegaly Center

Research & Reviews  2,155 results

Proteomic Identification and Clinicopathologic Characterization of Splenic Amyloidosis.
https://doi.org/10.1097/PAS.0000000000001948
The American Journal of Surgical Pathology; Chiu A, Dasari S et. al.

Aug 16th, 2022 - The spleen is a commonly encountered specimen in surgical pathology. However, little is known about the incidence, morphologic pattern, and clinical features of spleens involved by amyloidosis. We retrospectively identified 69 spleen amyloid cases...

Why Is Health Care for Children with Down Syndrome So Crucial from the First Days of Li...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367785
International Journal of Environmental Research and Publi... Telman G, Sosnowska-Sienkiewicz P et. al.

Aug 13th, 2022 - Down syndrome (DS) is a common genetic disorder and is associated with an increased likelihood of many diseases, including defects of the heart, genitourinary system, gastrointestinal tract, and oncological diseases. The aim of this study was to a...

Rare case of upper gastrointestinal hemorrhage due to accessory spleen: A case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351849
Medicine Liu Y, Dai Y et. al.

Aug 11th, 2022 - Upper gastrointestinal hemorrhage (UGIH) is defined as hemorrhage originating from the gastrointestinal tract proximal to the ligament of Treitz. The causes of UGIH include esophagitis, gastritis, peptic ulcers, Mallory-Weiss syndrome, and cancer....

Noncirrhotic Portal Hypertension after Trastuzumab Emtansine in HER2-positive Breast Ca...
https://doi.org/10.1148/radiol.220536
Radiology Choi SJ, Lee SS et. al.

Aug 10th, 2022 - Background Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for use in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Case reports have suggested an association between T-DM1 and portal hypertension. Pu...

Incidental splenomegaly in a teenager.
https://doi.org/10.1136/archdischild-2022-324133
Archives of Disease in Childhood. Education and Practice ... Baghin V, Prader S et. al.

Aug 9th, 2022 - Incidental splenomegaly in a teenager.|2022|Baghin V,Prader S,Sirin S,Pachlopnik Schmid J,Trück J,|

see more →

Guidelines  1 results

Revised diagnostic criteria and classification for the autoimmune lymphoproliferative s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953894
Blood Oliveira JB, Bleesing JJ et. al.

Jun 12th, 2010 - Lymphadenopathy in children for which no infectious or malignant cause can be ascertained constitutes a challenging diagnostic dilemma. Autoimmune lymphoproliferative syndrome (ALPS) is a human genetic disorder of lymphocyte apoptosis resulting in...

see more →

Drugs  12 results see all →

Clinicaltrials.gov  101 results

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-e...
https://clinicaltrials.gov/ct2/show/NCT03952039

Aug 1st, 2022 - This Phase 3, multicenter, randomized, two-arm, open-label study will include subjects with intermediate or high-risk (as per the DIPSS score) primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (post-PV MF), or post-essential thrombo...

Lysosomal Acid Lipase (LAL) Deficiency Registry
https://clinicaltrials.gov/ct2/show/NCT01633489

Jul 29th, 2022 - Lysosomal Acid Lipase (LAL) Deficiency is a rare autosomal recessive lysosomal storage disorder (LSD) that is caused by a marked decrease of lysosomal acid lipase (LAL), the enzyme that breaks down cholesteryl esters and triglycerides in the lysos...

A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease
https://clinicaltrials.gov/ct2/show/NCT04002830

Jul 22nd, 2022 - Patients with Type 3 GD exhibit both visceral and neurologic manifestations. In addition to the progressive neurologic involvement, somatic disease manifestations, especially splenomegaly and resulting cytopenia, contribute to significant mortalit...

Natural History of Noncirrhotic Portal Hypertension
https://clinicaltrials.gov/ct2/show/NCT02417740

Jul 22nd, 2022 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...

Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT03208803

Jul 20th, 2022 - Myeloproliferative Neoplasms are chronic diseases; they encompass Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis with shared mutations that constitutively activate the physiologic signal-transduction pathways responsible f...

see more →

News  235 results

Pacritinib Paves a “Unique Lane” of Treatment for Select Myelofibrosis
https://www.onclive.com/view/pacritinib-paves-a-unique-lane-of-treatment-for-select-myelofibrosis

Apr 5th, 2022 - Patients who develop post–essential thrombocythemia myelofibrosis (PET-MF) or post–polycythemia vera myelofibrosis (PPV-MF), which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effecti...

NCCN Recommends Ropeginterferon Alfa-2b in Clinical Practice Guidelines Update
https://www.onclive.com/view/nccn-recommends-ropeginterferon-alfa-2b-in-clinical-practice-guidelines-update

Mar 24th, 2022 - The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology has been revised to include ropeginterferon alfa-2b-njft (Besremi) as a recommended treatment option for adult patients with polycythemia vera, according to ...

The Clinical Course for MF and Changing Therapies
https://www.onclive.com/view/the-clinical-course-for-mf-and-changing-therapies

Mar 7th, 2022 - Ruben Mesa, MD: So, we have these patients, we’ve started them on therapy, at the current time with MF [myelofibrosis] we have ruxolitinib or fedratinib, likely soon pacritinib. Angela, what does that course typically look like? When might you exp...

An Introduction to Myeloproliferative Neoplasms
https://www.onclive.com/view/an-introduction-to-myeloproliferative-neoplasms

Feb 17th, 2022 - Ruben Mesa, MD:Hello and welcome to this OncLive® Peer Exchange titled Myeloproliferative Neoplasms. I’m Dr Ruben Mesa, the executive director of the Mays Cancer Center at UT Health San Antonio MD Anderson. Joining me in today’s discussions are my...

Treatment of Older Patients With ITP
https://www.onclive.com/view/treatment-of-older-patients-with-itp

Feb 9th, 2022 - James Bussel, MD: Craig, you promised to share your wisdom about how to manage the older patients with ITP [immune thrombocytopenic purpura] because there are changes in responses and especially adverse effects for some of the treatments we might ...

see more →

Patient Education  3 results see all →